Skip to main content
. Author manuscript; available in PMC: 2024 Mar 22.
Published in final edited form as: Pediatr Blood Cancer. 2022 Oct 2;70(1):e30005. doi: 10.1002/pbc.30005

Table 2.

Irinotecan/temozolomide treatment for recurrent Ewing sarcoma: comparison of 5 day and 10 day schedules of administration

Irinotecan dose schedule
Daily x 5 days x 2 weeks (10 doses) Daily x 5 days x 1 week (5 doses)
Patients Objective responses Patients Objective responses
89 47 (53%) 180 52 (29%)